Fat-associated lymphoid clusters in the peritoneal, pericardial, and pleural cavity of mice are storage sites for lymphoid cells (9) and have been implicated in myocardial fibrosis after myocardial infarct (heart attack) (10). In addition, a distinct population of GATA-binding protein 6–positive (GATA6⁺) macrophages reside in all three major cavities, depend on retinoic acid for their identity, and retain their cavity gene expression signature regardless of whether they are in the peritoneal, pleural, or pericardial space (11). These cells accumulate rapidly at sites of organ injury and affect healing from the outside (12). Comparably, Cugurra et al. and Brioschi et al. illustrate that the brain and spinal cord harbor an exclusive pool of immune cells in the meninges that influence CNS diseases. Clearly, many organs have an immune presence localized to their borders, but the degree to which these cells are solicited to the parenchyma is unclear.

The wealth of immune cells that surround various organs also raises the issue of immune cell recruitment. The canonical manner by which immune cells are recruited is through the vasculature and, in most cases, by extravasation from the post-capillary venules (13). However, Cugurra et al., Brioschi et al., and others (4, 12) have raised the possibility that immune cells could be recruited through the process of “invasion,” which involves migration into an organ from the perimeter, perhaps even by way of an avascular route. Having a pool of mature immune cells surrounding an organ provides a critical, immediately available reservoir of specific immune cells. For example, recruitment of monocytes from bone marrow to tissues where they become mature macrophages to initiate repair could take days, especially if new vasculature needs to be constructed. By contrast, a population of mature monocytes in the CNS, or mature GATA6⁺ macrophages in visceral cavities, are poised to instantly respond to brain, heart, or lung injury.

The findings of Cugurra et al. and Brioschi et al. suggest that the blood-brain barrier does not necessarily need to be disrupted for meningeal immune cells to infiltrate the brain parenchyma. The clinical implications are numerous. For example, gliomas are primary brain tumors that are notoriously difficult to treat. Infiltrating monocytes have been shown to promote tumorigenesis (14). It would be fascinating to exploit the skull-meninges connections to influence myeloid cell chemotaxis as an immunotherapeutic option. Moreover, there is currently no medical treatment available for traumatic brain injury. Recent data show that myeloid cells promote vascular repair after traumatic brain injury (15). Perhaps the skull marrow myeloid cell reservoir can be harnessed as an immediate source of reparative cells.

It remains unknown whether there are specific CNS signaling molecules that preferentially recruit meningeal immune cells over blood-derived cells. Is this also the case for visceral organs, heart, and lungs? Furthermore, the temporal dynamics of infiltration of CNS-marrow–derived versus blood-derived cells versus cavity immune cells needs to be explored and evaluated against disease progression. In surgical interventions, inadvertent removal of the border pericardium (during heart surgery), fusion of the pleural space (to limit effusions), craniotomy (removal of part of the skull), or durotomy (perforation of the dura mater meningeal membrane) can occur. What are the implications of these procedures for these cell niches and the physiological responses of an organ? The studies of Cugurra et al. and Brioschi et al. remind us that there is a vast amount of immunity that surrounds each organ with a coterie of immune cells with distinct phenotypes. In the case of the brain, it provides yet another specialized layer that should be considered in the context of the CNS.

**REFERENCES AND NOTES**

16. Published by AAAS

**VIEWPOINT: COVID-19**

**Scent of a vaccine**

Intranasal vaccination should block SARS-CoV-2 transmission at the source

By Frances E. Lund and Troy D. Randall

The highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects the respiratory tract and is transmitted, in part, by respiratory droplets and aerosols. Consequently, unvaccinated people are encouraged to wear masks in public, self-quarantine if symptomatic, and practice social distancing. Despite these precautions, millions are dying. As the pandemic takes its toll, vaccines are once again headline news, notably for the speed of their development and the success of messenger RNA (mRNA) vaccines. Given the respiratory tropism of the virus, however, it seems surprising that only seven of the nearly 100 SARS-CoV-2 vaccines currently in clinical trials are delivered intranasally. Advantages of intranasal vaccines include needle-free administration, delivery of antigen to the site of infection, and the elicitation of mucosal immunity in the respiratory tract. The idea that intranasal vaccination preferentially protects the respiratory tract is not new: Development of the US Food and Drug Administration (FDA)–approved live attenuated influenza vaccine (LAIV) began in the 1960s. Immunologists have long known that nasal infection or vaccination elicits an immunoglobulin A (IgA) response in both serum and respiratory fluids, whereas intramuscular vaccines primarily elicit serum IgG. IgA is particularly important in the upper airways and nasal passages, where it is actively transported across the epithelium and released into the airway lumen as a dimer bound to secretory component, a stabilizing configuration that allows it to more effectively neutralize viruses like SARS-CoV-2 (1). By contrast, IgG enters and protects the lower lung through passive transudation across the thin alveolar epithelium (2). IgG is also found in the upper respiratory tract and nasal passages.

*Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA. 2Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Email: randall@uab.edu*
In transnasal delivery triggers long-lasting, virus-neutralizing serum IgG responses as well as antigen-specific IgA and CD8+ T cells in the respiratory tract (6–8). Moreover, both intranasal and intramuscular vaccination with adenovirus-vectored vaccines protect against pneumonia and weight loss after a challenge infection. However, animals vaccinated intramuscularly still shed virus from the nasal passages, whereas animals vaccinated intranasally have reduced viral replication and shedding in both the lungs and the nasal passages (8).

“...it seems surprising that only seven of the nearly 100 SARS-CoV-2 vaccines currently in clinical trials are delivered intranasally.”

Adenoviruses are natural human pathogens, and many adults have been exposed to one or more strains, meaning that they may have antivector antibodies that impair vaccine efficacy (negative interference). However, Ad5-vectored intranasal influenza vaccine (NasoVAX), administered at high doses, works similarly in Ad5 seropositive and seronegative individuals (9), perhaps because the inoculating volume dilutes local antibody concentrations. Nevertheless, in an attempt to avoid any potential negative interference, some developers are using rare strains of human adenoviruses or chimp adenoviruses, to which most humans have not been exposed.

The influenza-vectored SARS-CoV-2 vaccine being developed by the University of Hong Kong may face related hurdles. The deletion of the influenza virus gene encoding nonstructural protein 1 (NS1) strongly attenuates the vector and allows developers to replace NS1 with the SARS-CoV-2 spike-RBD. Like adenovirus-vectored vaccines, this one should also elicit mucosal IgA against RBD and place resident memory cells in the respiratory tract. However, negative interference from preexisting antibodies against the influenza vector may impair its effectiveness. Similarly, Meissa Vaccines developed a live attenuated respiratory syncytial virus (RSV) vector in which it replaced the RSV F and G host receptor proteins with SARS-CoV-2 spike. Delivered intranasally, the chimeric virus should elicit mucosal immunity. Notably, the change in surface proteins will likely alter the cellular tropism of the virus and perhaps its immunogenicity. Preexisting antibodies against RSV should not interfere with vaccination, but preexisting antibodies against spike may neutralize it.

Live attenuated SARS-CoV-2 intranasal vaccines should also effectively elicit mucosal IgA responses and resident-memory cells in the respiratory tract. Unlike vectored vaccines that express only spike or RBD, live attenuated SARS-CoV-2 has the advantage of expressing (and potentially eliciting immune responses against) all viral proteins, thereby conferring broad-spectrum immunity that should cross-react with and provide some level of immunity against variant strains of SARS-CoV-2. Although modern molecular techniques minimize the risk of reversion, live attenuated viruses retain replicative capacity and are contraindicated for infants <2 years, people aged >49 years, or immune-compromised persons. Live attenuated SARS-CoV-2 and spike-expressing RSV may also face scrutiny over their potential to cause neuronal symptoms (10).

Past experience with LAIV will be relevant to these live attenuated vaccines. In

### Intransanal SARS-CoV-2 vaccines in clinical trials

<table>
<thead>
<tr>
<th>NAME</th>
<th>DEVELOPER</th>
<th>TYPE (ANTIGEN)</th>
<th>CLINICAL TRIAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>ChAdOx1-S</td>
<td>University of Oxford</td>
<td>Chimpanzee adenovirus vector (spike)</td>
<td>NCT04816019 (phase 1)</td>
</tr>
<tr>
<td>AdCoV1D</td>
<td>Alim孵化</td>
<td>Adenovirus 5 vector (RBD)</td>
<td>NCT04679909 (phase 1)</td>
</tr>
<tr>
<td>BBV154</td>
<td>Bharat Biotech</td>
<td>Simian adenovirus vector (spike)</td>
<td>NCT04751682 (phase 1)</td>
</tr>
<tr>
<td>DelNSi-CoV-RBD LAIV</td>
<td>University of Hong Kong</td>
<td>Live attenuated influenza virus (RBD)</td>
<td>NCT04809389 (phase 1)</td>
</tr>
<tr>
<td>MV-014-212</td>
<td>Meissa Vaccines</td>
<td>Live attenuated RSV (spike)</td>
<td>NCT04798001 (phase 1)</td>
</tr>
<tr>
<td>COVI-VAC</td>
<td>Codagenix</td>
<td>Live attenuated SARS-CoV-2</td>
<td>NCT04619628 (phase 1)</td>
</tr>
<tr>
<td>CIBG-669</td>
<td>Center for Genetic Engineering and Biotechnology, Cuba</td>
<td>Protein subunit AgnHB (RBD)</td>
<td>RPCE000000345 (phase 1/2)</td>
</tr>
</tbody>
</table>

HB, hepatitis B virus; RBD, receptor binding domain; RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
children, intranasal LAIV is generally superior to intramuscular vaccination (11). This success likely reflects the immunological naïveté of children (most have not been exposed to influenza virus). As a result, there is no immune barrier to LAIV infection in the nasal passages and vaccine “take” is efficient, leading to robust mucosal IgA responses and the placement of tissue-resident memory cells in the airways. LAIV is also effective in adults, but not necessarily better than intramuscular vaccination (11), in part because prior influenza virus infection has established a baseline of immunity that impairs the infectivity of LAIV. Consequently, live attenuated SARS-CoV-2 vaccines may elicit robust protection in native individuals, but preexposed individuals may have sufficient immunity to neutralize the vaccine, rendering it ineffective even as a booster.

Only one of the intranasal vaccines in clinical trials is insert—the human CIBP-669, which consists of RBD linked to the hepatitis B virus core antigen, a potent stimulator of T cells. Because insert vaccines do not rely on infection or gene expression, they cannot be neutralized by preexisting antibodies. However, soluble proteins delivered to the nasal passages do not efficiently breach the epithelium. Instead, they must be transported across the epithelial barrier by specialized microfold (M) cells (12), which deliver antigens to immune cells underneath the epithelium.

Notably absent from the list of intranasal vaccines are those formulated as lipid-encapsulated mRNA. Delivered intramuscularly, mRNA vaccines elicit high titers of serum IgG against encoded antigens. Rodent studies suggest that mRNA vaccines are also efficacious when delivered intranasally (13). However, it is important to distinguish intranasal delivery and nasal vaccination. Rodents are often anesthetized for intranasal vaccination and infection, causing them to take slow, deep breaths that deliver the inoculum all the way into the lung. As a result, much of the literature (including some cited here) on intranasal vaccination in rodents actually refers to intrapulmonary vaccination, which may provide more complete protection than strictly nasal vaccination. Nevertheless, resident memory cells in the nasal passages can prevent virus dissemination to the lung (4). Given that vaccine delivery to the lower respiratory tract may directly cause inflammation or may exacerbate conditions such as asthma or chronic obstructive pulmonary disease (COPD), intranasal vaccines are typically administered to humans in a way that prevents antigen delivery to lungs.

Lipid formulation is critical for mRNA vaccine stability, for cell targeting, and for releasing mRNA to the cytosol. Thus, the future success of intranasal mRNA vaccines will likely hinge on developing lipid nanoparticles that target the appropriate cell types in the nasal passages. Unlike viruses and viral vectors, lipid nanoparticles lack proteins on their surface and should not be neutralized by antibodies, making the same formulation viable for repeated vaccination. However, adverse events such as fatigue and malaise are frequently linked to mRNA vaccination. Therefore, intranasal mRNA vaccines should be developed cautiously to avoid side effects and reactogenicity.

Ultimately, the goal of vaccination is to elicit long-lived protective immunity. However, the duration of serum antibody responses varies considerably, depending on poorly understood attributes of the initiating antigen (14). Mucosal antibody responses are often considered short-lived, but their actual duration may depend on how antigen is encountered. Similarly, recirculating central-memory T cells are self-renewing and persist for long periods, whereas lung-resident memory T cells wane relatively rapidly—more so for CD8+ T cells than for CD4+ T cells. Thus, intranasal vaccines may have to balance the goal of local immunity in the respiratory tract with the longevity of systemic immunity. However, effective vaccination strategies need not be restricted to a single route. Indeed, memory cells primed by intramuscular vaccination can be “pulled” into mucosal sites by subsequent mucosal vaccination (15). Thus, the ideal vaccination strategy may use an intramuscular vaccine to elicit a long-lived systemic IgG response and a broad repertoire of central memory B and T cells, followed by an intranasal booster that recruits memory B and T cells to the nasal passages and further guides their differentiation toward mucosal protection, including IgA secretion and tissue-resident memory cells in the respiratory tract.

REFERENCES AND NOTES

9. S. Tasker et al., Vaccines (Basel) 9, 224 (2021).

ACKNOWLEDGMENTS

F.E.L. and T.D.R. are consultants for, and receive research funding from, Altlimmune Inc.

10.1126/science.abg9857